Chi­na's biotech pipeline is brim­ming with PD-1/L1 check­points. Are they re­al­ly need­ed?

The big US and Eu­ro­pean mar­kets aren’t the on­ly place where PD-1/L1 check­point drugs are crowd­ing in. Be­gin­ning lat­er this year, the da­ta an­a­lyt­ics firm Pharm­Cube re­ports, Keytru­da and Op­di­vo should both be green light­ed for mar­ket­ing in Chi­na. And they’ll like­ly be swift­ly fol­lowed by 4 Chi­nese bio­phar­mas an­gling for their own share of the mar­ket — with a dozen more be­hind them prepar­ing to make an im­pact on Chi­na and the world.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.